#United States #Plantation #CDMO #GBI Biomanufacturing #Chandra Kelley

GBI Biomanufacturing Welcomes Chandra Kelley as Chief Business Officer

On May 27, 2026, GBI Biomanufacturing, Inc. (GBI), a prominent player in the biologics Contract Development and Manufacturing Organization (CDMO) landscape, made headlines with the announcement of Chandra Kelley's appointment as the Chief Business Officer (CBO). This strategic move is anticipated to bolster GBI’s commercial endeavors and growth trajectory as the company continues to enhance its capabilities and expand its market footprint.

Experienced Leadership for Expanding Operations

Chandra Kelley joins GBI with over 25 years of experience in the biotech and biopharmaceutical sectors. Her extensive background includes significant achievements in driving commercial growth, fostering strategic collaborations, and building customer-centric sales teams focused on large molecule development and manufacturing services. Prior to her role at GBI, Kelley held pivotal senior positions at KBI Biopharma, Pfanstiehl, and SAFC, solidifying her expertise in the industry.

Jesse McCool, President of GBI Biomanufacturing, expressed enthusiasm about Kelley’s appointment, stating, "GBI Biomanufacturing is entering an exciting new phase of growth and capability expansion. Chandra brings the client and market insights needed to deepen the way we support our early-stage antibody and ADC projects. Her experience structuring integrated and phase-appropriate work packages for rapid early-phase supply aligns exceptionally well with GBI's latest solutions in the mAb and bioconjugation space."

As CBO, Kelley will take the helm of the company’s commercial strategy, business development initiatives, and client engagement pursuits, all while focusing on long-term growth planning. She aims to enhance GBI’s customer base, refine strategic partnerships, and improve the evaluation processes for proposals and projects, ensuring alignment between commercial execution and operational capabilities to foster sustainable growth.

A Vision for Future Growth

In her own words, Kelley stated, "I'm excited to join GBI at such a dynamic stage of growth. GBI recently built an impressive expansion in South Florida that adds commercial-scale production capacity for complex biologics, complementing the company's long-standing expertise in mammalian-based production of recombinant proteins. What stands out most is the organization's commitment to scientific excellence, operational flexibility, and their unmatched customer service. I look forward to partnering with the team to further strengthen GBI's position as a trusted CDMO partner supporting clients from development through commercialization."

GBI Biomanufacturing has over three decades of operational experience in South Florida, establishing itself as a fully integrated partner in biologics development and manufacturing. The company supports a wide array of biologic modalities, including protein biologics, bioconjugates, exosomes, and stem cell therapies. This comprehensive approach facilitates the seamless advancement of programs from early development stages to commercialization—allowing clients to collaborate with a single CDMO partner throughout the process.

Advanced Capabilities and Commitment to Excellence

From cell line development to the final drug product fill and finish, GBI provides GMP manufacturing across various single-use bioreactor scales, including 50 L, 200 L, 500 L, and 2000 L fed-batch systems, alongside perfusion platforms. The organization’s in-house semi-automated and automated fill lines amplify efficiency, enabling early-stage drug product manufacturing and drug substance production to occur under one roof, creating a streamlined Single-Source Solution™ workflow.

Moreover, for programs advancing beyond Phase 1, GBI utilizes strategic manufacturing partnerships to ensure readiness for continued expansion and commercialization.

About GBI Biomanufacturing

GBI Biomanufacturing is a Florida-based CDMO dedicated to minimizing manufacturing risks for developers of intricate biologic therapies. Over the last 30 years, the company has supported more than 400 large-molecule projects and 50 regulatory filings, showcasing resilient platforms and service capabilities. With robust process development, cutting-edge manufacturing infrastructure, and a network of strategic subcontractors and suppliers, GBI is committed to delivering reliable, end-to-end CDMO partnerships for biologics programs through a blend of scientific expertise and practical innovation tailored to each project.

For further inquiries, please contact:
Yaslin Alicea–Hidrovo
Business Development and Marketing Specialist
GBI Biomanufacturing
1850 NW 69th Ave, Plantation FL 33313
Phone: +1 (954) 256-0585
Email: [email protected]

This recent leadership appointment marks a crucial step for GBI Biomanufacturing as it strives to enhance its role as a frontrunner in the biologics manufacturing space, fully embracing the new market possibilities that lie ahead.